United Health Products (UEEC) 10-K 15 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Apr. 15, 2014	Jun. 28, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'UNITED HEALTH PRODUCTS, INC.	'	'
Entity Central Index Key	'0001096938	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Is Entity a Well-known Seasoned Issuer	'No	'	'
Is Entity a Voluntary Filer	'No	'	'
Is Entity's Reporting Status Current	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	102,647,640	'
Entity Public Float	'	'	$3,302,160
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and Cash Equivalents	$1,855	$32
Inventory	33,651	'
Total current assets	35,506	32
Other Assets	'	'
Intangible Assets, Net	50,000	150,000
TOTAL ASSETS	85,506	150,032
Current Liabilities	'	'
Accounts payable and accrued expenses	285,457	770,695
Liability for unissued shares	160,543	496,723
Notes payable - related parties	625,224	448,099
Other current liabilites	136,106	123,905
Total current liabilities	1,207,330	1,839,422
Commitments and Contingencies	'	'
Stockholders' Deficiency	'	'
Common Stock - $.001 par value, 150,000,000 Shares Authorized, 102,260,140 and 84,644,133 Shares Issued and Outstanding at December 31, 2013 and December 31, 2012, respectively	102,260	84,644
Additional Paid-In Capital	6,299,869	4,623,553
Accumulated Deficit	-7,523,953	-6,397,587
Total Stockholders' Deficiency	-1,121,824	-1,689,390
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$85,506	$150,032

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Deficiency	'	'
Common Stock, par value	$0.00	$0.00
Common Stock, Authorized	150,000,000	150,000,000
Common Stock, Issued	102,260,140	84,644,133
Common Stock, Outstanding	102,260,140	84,644,133

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements Of Operations	'	'
Revenues	$3,060	'
Operating Costs and Expenses	'	'
Amortization of Intangibles	100,000	100,000
Selling, general and administrative expenses	1,219,767	107,018
Total Operating Expenses	1,319,767	207,018
Loss from Operations	-1,316,707	-207,018
Other income (expenses)	'	'
Other Income	259,043	'
Interest Expense, Net	-68,702	-74,395
Total other income (expense)	190,341	-74,395
Net Loss	($1,126,366)	($281,413)
Net Loss per common share:	'	'
Basic and diluted	($0.01)	$0
Weighted average number of shares outstanding	94,403,138	83,368,821

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Deficit (USD $)	Common Stock	Additional Paid-In Capital	Retained Earnings / Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2011	$80,840	$4,510,882	($6,116,174)	($1,524,452)
Beginning Balance, Shares at Dec. 31, 2011	80,840,394	'	'	'
Issuance of Common Stock in connection with conversion of indebtedness to related party, Amount	2,454	55,021	'	57,475
Issuance of Common Stock in connection with conversion of indebtedness to related party, Shares	2,453,739	'	'	'
Issuance of Common Stock in connection with services, Amount	350	18,650	'	19,000
Issuance of Common Stock in connection with services, Shares	350,000	'	'	'
Issuance of Common Stock in connection with services, resignations and forfeited options, Amount	1,000,000	'	'	'
Issuance of Common Stock in connection with services, resignations and forfeited options, Shares	1,000	39,000	'	40,000
Net Loss	'	'	-281,413	-281,413
Ending Balance, Amount at Dec. 31, 2012	84,644	4,623,553	-6,397,587	-1,689,390
Ending Balance, Shares at Dec. 31, 2012	84,644,133	'	'	'
Issuance of Common Stock in connection with conversion of indebtedness to related party, Amount	11,706	339,474	'	351,180
Issuance of Common Stock in connection with conversion of indebtedness to related party, Shares	11,706,007	'	'	'
Issuance of Common Stock in connection with services, Amount	8,000	967,269	'	975,269
Issuance of Common Stock in connection with services, Shares	8,000,000	'	'	'
Forfeiture of shares, Amount	-2,090	2,090	'	'
Forfeiture of shares, Shares	-2,090,000	'	'	'
Capital contributed	'	367,483	'	367,483
Net Loss	'	'	-1,126,366	-1,126,366
Ending Balance, Amount at Dec. 31, 2013	$102,260	$6,299,869	($7,523,953)	($1,121,824)
Ending Balance, Shares at Dec. 31, 2013	102,260,140	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash Flows from Operating Activities:	'	'
Net Loss	($1,126,366)	($281,413)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:	'	'
Depreciation and Amortization	100,000	100,000
Interest accrued	68,702	74,395
Issuance of Stock Based Compensation	975,269	40,000
Changes in assets and liabilities:	'	'
Accounts Payable and Accrued Expenses	-136,403	64,837
Net Cash Used In Operating Activities	-118,798	-2,181
Cash Flows from Financing Activities:	'	'
Proceeds from Related Parties	120,621	1,987
Increase (Decrease) in Cash and Cash Equivalents	1,823	-194
Cash and Cash Equivalents - Beginning of period	32	226
CASH AND CASH EQUIVALENTS - END OF PERIOD	1,855	32
Schedule of Non-Cash Financing Activities:	'	'
Issuance of Common Stock in connection with Conversion of Convertible Notes and Related Interest	351,180	104,109
Issuance of Common Stock in connection with Services	975,269	'
Capital Contributed	$367,483	'

Organization_and_Basis_of_Prep

Organization and Basis of Preparation	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
1. Organization and Basis of Preparation	'
	United Health Products, Inc. (formerly United EcoEnergy Corp.) (“United” or the “Company”) is a product development and solutions company focusing its growth initiatives on the expanding wound-care industry and disposable medical supplies markets. The Company produces an innovative gauze product that absorbs exudate (fluids which have been discharged from blood vessels) by forming a gel-like substance upon contact. Epic Wound Care, Inc. (“Epic”), the Company’s principal operating subsidiary, was dissolved by the State of Florida and, accordingly, all operations are now directly in the Company.
	While the Company has funded its initial operations with private placements and secured loans from a related party, there can be no assurance that adequate financing will continue to be available to the Company and, if available, on terms that are favorable to the Company. The Company’s ability to continue as a going concern is also dependent on many events outside of its direct control, including, among other things, improvement in the economic climate. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
2. Significant Accounting Policies	'
	Consolidation
	The accompanying consolidated financial statements include the accounts of the Company and its former wholly owned subsidiary, Epic Wound Care, Inc. (which was recently dissolved by the State of Florida), as of the dates and for the fiscal years indicated. All intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.
	Income Taxes
	The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities which is commonly known as the asset and liability method. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	The Company evaluates its tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are ‘‘more-likely-than-not’’ of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are recorded as an expense in the applicable year. The Company does not have a liability for any unrecognized tax benefits. Management’s evaluation of uncertain tax positions may be subject to review and adjustment at a later date based upon factors including, but not limited to, an on-going analysis of tax laws, regulations and interpretations thereof, with due consideration given to the fact that tax periods are open to examination by tax authorities. Management believes the Company is no longer subject to income examinations for years prior to 2010.
	As of December 31, 2013, the Company has approximately $6.1 million of net operating loss carry-forwards available to affect future taxable income and has established a valuation allowance equal to the tax benefit of the net operating loss carry forwards and temporary differences as realization of the asset is not assured.
	Revenue Recognition
	The Company recognizes revenues when persuasive evidence of an arrangement exists, product has been delivered or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is recognized net of estimated sales returns and allowances.
	Revenues are attributable to the sale of medical products through distributor agreements. The principal terms of the agreements provide that the distributor orders be accompanied by partial payment in advance, which at least equals 50% of total manufactured cost, as defined, for orders for distributor inventory and, in addition, an agreed portion of the distributor’s gross profit on special orders. The balance of the manufactured cost is due from the distributor at the time of shipment. The Company is also entitled to an agreed percentage of the distributor’s profit on receipt by the distributor. The Company defers all amounts received in advance of shipment and recognizes as revenue the aggregate of amounts invoiced in advance and an estimate of the Company’s portion of distributor’s profit at the time of shipment.
	Per Share Information
	Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted loss per share is the same as basic loss per share, as the effect of potentially dilutive securities (8,150,000 options and 1,698,378 warrants at December 31, 2012 and 2,650,000 options and 1,698,378 warrants at December 31, 2013), is anti-dilutive.
	New Accounting Pronouncements
	Recently Adopted Accounting Pronouncements
	In July 2012, the FASB issued an Accounting Standards Update that added an optional qualitative assessment for determining whether an indefinite-lived intangible asset is impaired. The objective of this update is to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by allowing an entity the option to make a qualitative evaluation about the likelihood of an intangible impairment to determine whether it should calculate the fair value of the asset. This accounting standards update also amends existing guidance by expanding upon the examples of events and circumstances that an entity should consider between annual impairment tests in determining whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount.
	The Company has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its Consolidated Financial Statements.

Acquisition_of_Intellectual_Pr

Acquisition of Intellectual Property Rights	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
3. Acquisition of Intellectual Property Rights	'
	In June 2009, the Company acquired the intellectual property rights of Epic Wound Care, LLC, through the then wholly-owned subsidiary, Epic Wound Care, Inc. (“Epic”). The intellectual property includes the right to manufacture and distribute innovative gauze to serve the wound care market. The acquisition cost for the rights was 30 million shares of Company’s common stock, of which 20 million shares were escrowed with the voting rights controlled by the Company pending attainment of certain performance targets over 18 months from the closing date of the transaction. The Company valued the rights acquired at $500,000 based upon the Company's expectation for commercialization of the rights less costs to effectuate applicable approvals.
	On March 8, 2011, the Company and Epic entered into a global settlement and release agreement (the “Settlement Agreement”) with various parties to resolve disputes regarding the Agreement and Plan of Acquisition, dated May 19, 2009, entered into by the Company in connection with its acquisition of the business and assets of Epic Wound Care, LLC (the “Acquisition Agreement”). The parties had differences of opinion concerning the satisfaction of certain milestones and conditions in the Acquisition Agreement in connection with the release of the escrowed shares mentioned above. The settlement provided for the release of 20 million escrowed shares to the sellers of the business and assets and the contribution of 2 million shares of the Company’s common stock to the capital of the Company (which were cancelled) to facilitate the settlement by certain non-controlling shareholders who provided investment advice to the Company on a regular periodic basis, including investment advice related to the Acquisition Agreement. As a condition to the settlement, the Board of the Directors of the Company waived certain milestones and conditions regarding the release of the escrowed shares as set forth in the Acquisition Agreement and the parties to the Settlement Agreement agreed to mutual releases and to resolve and settle any and all claims, controversies, disputes and causes of action, whether asserted or unasserted, known or unknown, real or potential, or whether in law, equity or otherwise, relating to, arising out of, or in any way concerning the Acquisition Agreement and the escrowed shares, without any admission of fault, liability or wrongdoing on the part of or on behalf of any party.
	The Company is amortizing the intangibles acquired over a five year period and, accordingly recorded an amortization charge of $100,000 in both 2013 and 2012.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
4. Related Party Transactions	'
	The Company’s transactions with LeadDog Capital LP were as follows:
		Year Ended December 31,
		2013		2012
	Balance at beginning of period	$	448,099	$	409,398
	New borrowings at 16% interest rate		-		1,987
	Interest accrued		56,504		56,039
	Amortization of loan discount		-		-
	Redemption of indebtedness by the issuance shares of common stock		-		(19,325	)
	Repayment		-		-
	Balance at end of period	$	504,603	$	448,099
	At December 31, 2013 and 2012, notes payable – related parties includes unpaid interest of $152,952 and $96,448, respectively. In 2011, the Board authorized the issuance of 1,000,000 shares to LeadDog Capital Markets LLC to extend the maturity dates of the outstanding loans to December 2012. The notes were payable within one year of the origination date of the notes or under extensions through December 2012. These notes were not paid on December 31, 2012 and no demand has been made for payment. LeadDog has advised the Company that a discrepancy exists as to the amount of monies owed to them. In November 2013, the Company commenced a lawsuit against LeadDog Capital LP and its affiliates seeking to cancel the indebtedness and the return for cancellation of all securities issued to LeadDog Capital LP and its affiliates.
	LeadDog Capital LP and its affiliates are shareholders and warrant holders; however, the group is restricted from becoming a beneficial owner (as such term is defined under Section 13(d) and Rule 13d-3 of the Securities Exchange Act of 1934, as amended, (the 1934 Act)), of the Company’s common stock which would exceed 9.5% of the number of shares of common stock outstanding.
	In addition, an officer of the Company loaned approximately $120,000 to the Company to cover operating expenses with no repayment terms or interest charge.

Issuances_of_Securities

Issuances of Securities	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
5. Issuances of Securities	'
	In February 2012, the Company redeemed $19,325 of indebtedness including interest to LeadDog Capital LP for 1,500,000 shares of common stock. The fair value of the common stock approximated the carry amount of the indebtedness at the time of the offer to convert.
	In February 2012, the Company issued 953,739 shares to LeadDog which was debt previously converted but shares were not actually issued and 350,000 shares to others which was for services previously recorded but not issued.
	On December 11, 2012, Jan E. Chason resigned as an officer and director of UHP and Michael Wiechnik resigned as a director of UHP. Mr. Chason's resignation was delivered to the board on December 12, 2012. In connection with the resignation both received 500,000 shares each in settlement of any outstanding monies owed and options open. As of the time of issuance, the Company recorded non-cash compensation charges of $40,000.
	In May 2013, the Company entered into an agreement with Bibicoff & MacInnis, Inc. to provide stockholder financial community and investor relations and to serve as a consultant to the Company’s Board of Directors as described in “Note 8.” In connection with said agreement, Mr. Bibicoff subscribed to purchase 507,864 shares of Common Stock at $.04 per share at a subscription price of $20,314. Mr. MacInnis subscribed to purchase 338,576 shares at $.04 per share at a subscription price of $13,543. In each case the subscription price is payable pursuant to promissory notes payable with interest at 1.5% quarterly and due February 21, 2016. These shares won’t be issued until the promissory notes are paid in full.
	In May 2013, the Company issued a $15,000 promissory note to MayerMeinberg for accounting and relating services rendered. The note was converted in December 2013 at $.08 per share into 187,500 shares, which shares were issued in January 2014.
	Enterprise Partners LLC made loans to the Company prior to 2009. These monies which totaled $175,781 plus accrued interest of $175,399.20 were transferred to Beplate & Associates on or about December 1, 2011. These notes automatically converted into 11,706,007 shares on March 31, 2012 and the shares were issued in June 2013.
	In July 2013, Dr. Forman voluntarily surrendered his ownership of 2,750,000 options and 2,090,000 shares of Common Stock of the Company.
	In August 2013, the Company entered into a consulting agreement with Douglas Beplate. Pursuant to said agreement, the Company retained Mr. Beplate for the exclusive purpose of developing and marketing its hemostatic gauze products. A signing bonus of 6,000,000 shares of Common Stock which resulted in recording compensation expense of $744,000 was agreed upon and was issued pursuant to the Company’s 2013 Employee Benefit and Consulting Services Compensation Plan. These 6,000,000 shares were issued in September 2013 after the Plan was filed with the Securities and Exchange Commission on Form S-8. In the event sales of the Company’s hemostatic gauze products exceed $10 million, the Company is required to pay Mr. Beplate a cash commission of ½ of 1% on all sales achieved by the Company.
	On October 1, 2013, the Company entered into an operating agreement with Hemo Manufacturing LLC as described under “Note 8.” Pursuant to said agreement, the Company issued 2,000,000 shares of restricted Common Stock valued at $231,270 to the managing member of Hemo Manufacturing LLC.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
6. Fair Value Measurements	'
	Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
	Level 1 — Quoted prices in active markets for identical assets or liabilities. The Company’s investment in securities held for sale is fair valued by this method.
	Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data.
	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
7. Litigation	'
	There are no legal proceedings pending or threatened against us, and we are unaware of any governmental authority initiating a proceeding against us, except as described below. On November 8, 2013, United Health Products, Inc. filed a Complaint in the Second Judicial District Court, State of Nevada, County of Washoe, against defendants LeadDog Capital LP, LeadDog Capital Markets LLC, Chris Messalas and Jan Chason, the Company’s former Chief Financial Officer. The Company alleges that the defendants engaged in a course of conduct to divert funds from the Company for unauthorized purposes and to fraudulently induce the Company to issue common stock to some or all of the defendants. It is also alleged that as part of the defendants’ conduct, the Company’s secured lender, LeadDog Capital LP, made a series of loans, evidenced by promissory notes, to the Company from 2010 through 2012 and that, as a result of these loans, LeadDog Capital LP gained undue control over the business affairs of the Company and as a result of this undue control, funds borrowed from LeadDog Capital LP were diverted to other portfolio healthcare companies to which the hedge fund had made loans through the actions of defendants, Jan Chason and Chris Messalas. The relief sought by the Company includes, without limitation, the cancellation of funds owed to LeadDog Capital LP, the return of shares of common stock issued to one or more defendants for cancellation as well as damages.

Material_Agreements_and_Other_

Material Agreements and Other Matters	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
8. Material Agreements and Other Matters	'
	In August 2012, the Company’s manufacturing agent in China of its gauze products which is registered and branded in the United States under the trademark HemoStyp™, received 510(k) approval from the U.S. Food and Drug Administration (“FDA”) to be sold as a Class I device. The Company has the ability to represent to distributors and customers that its gauze products meet all FDA requirements as a Class I device. This approval now allows us to expand our potential customer base and pursue accounts that requested a current 510(k) FDA approval, including the prescription based medical arena, retail, hospital, EMS, military, state and national governmental agencies and veterinary markets.
	Epic entered into a corporate sponsorship agreement with American Diabetes Association (the “ADA”) on July 29, 2010 that was to become effective on November 1, 2010. This agreement enables Epic to act as a sponsor of the ADA’s programs and utilizes the ADA’s trademarks and logos in association with Epic’s products, as approved by the ADA. The agreement has a three-year term expiring October 31, 2013, subject to a mutual option to renew. The annual cost of the agreement is $400,000. The Company and the ADA have informally agreed to defer the implementation date of this agreement due to the matter discussed in the paragraph above and until the Company obtains additional financing.
	In May 2013, the Company entered into an agreement with Bibicoff & MacInnis, Inc. to provide stockholder financial community and investor relations and to serve as a consultant to the Company’s Board of Directors. The agreement became effective May 1, 2013 and terminates on October 30, 2014. If the agreement is not terminated by September 1, 2014, the agreement will convert to a month-to-months basis after October 2014 until cancelled with 60 days prior written notice. Fees payable to Bibicoff are $8,000 per month for the first four months, increasing to $11,000 per month for the next four months and increasing to $13,000 per month thereafter. The agreement with Bibicoff also requires the payment of certain fees to Bibicoff in connection with financing transactions. In connection with said agreement, Mr. Bibicoff subscribed to purchase 507,864 shares of Common Stock at $.04 per share at a subscription price of $20,315. Mr. MacInnis subscribed to purchase 338,576 shares at $.04 per share at a subscription price of $13,543 (see note 5 above).
	On October 1, 2013, the Company entered into an Operating Agreement with Hemo Manufacturing LLC. Hemo Manufacturing is to act as the exclusive supplier of manufactured products for the Company’s products. Pursuant to said agreement, 2,000,000, valued at $231,270, restricted shares of the Company’s Common Stock were issued. Under certain conditions, an additional 2,000,000 shares of the Company’s Common Stock would be issued in the event the Company is bought out by a third party. The Company anticipates booking all sales directly to customers and making payment for goods directly to Hemo Manufacturing. The managing member of Hemo Manufacturing will retain 100% of the profits earned by Hemo Manufacturing unless the Company is sold to a third party. In the event of such a sale, the managing member of Hemo Manufacturing and the Company would have equal share in the gross profits.
	In 2013, the Company entered into distribution agreements for Australasia and the military and the equestrian, dental and U.S. military markets.
	In August 2013, the Company entered into a consulting agreement with Douglas Beplate. Pursuant to said agreement, the Company retained Mr. Beplate for the exclusive purpose of developing and marketing its hemostatic gauze products. A signing bonus of 6,000,000 shares of Common Stock which resulted in recording compensation expense of $744,000 was agreed upon and was issued pursuant to the Company’s 2013 Employee Benefit and Consulting Services Compensation Plan. These 6,000,000 shares were issued in September 2013 after the Plan was filed with the Securities and Exchange Commission on Form S-8. In the event sales of the Company’s hemostatic gauze products excel $10 million, the Company is required to pay Mr. Beplate a cash commission of ½ of 1% on all sales achieved by the Company.
	In August 2013, the Company entered into an agreement with Melwood Partners. Pursuant to said agreement, the Company agreed to remove the restrictive legend on 250,000 shares owned by Melwood Partners and Melwood Partners agreed to cancel all cash and stock compensation owed to it by the Company. The Company agreed to enter into a new marketing agreement with Melwood Partners within 45 days on terms to be mutually agreed upon, however no said agreement has been entered into as of the filing date of this Form 10-K.

Other_Current_Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
9. Other Current Liabilities	'
	As of December 31, 2013, included in other current liabilities are four outstanding notes to various individuals aggregating approximately $136,100 in principal and accrued interest. Interest accrues at the rate of 9% - 14% per annum.
	In October 2010, in connection with the issuance of one of these notes due in November 2010, with a face value of $75,000, the Company also issued 250,000 shares of common stock. The discount attributable to the issuance of common stock ($20,100) was expensed over the period the debt was to be outstanding. The allocation was based upon the relative fair values of the securities issued in the transaction.

Board_Resignations

Board Resignations	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
10. Board Resignations	'
	On December 10, 2012, the Company entered into a Resignation Agreement with Jan E. Chason. Pursuant to said agreement, Mr. Chason agreed to release the Company from all monies owed to him, except for $50,000 which shall be paid to him without interest or deduction therefrom on December 11, 2013. Mr. Chason, who owned 1,000,000 shares of Common Stock at the time of his execution of said agreement, received an additional 500,000 shares of restricted Common Stock for a total of 1,500,000 shares, subject to a 9-month lockup through September 11, 2013. As part of the consideration for this transaction, Mr. Chason also agreed to cancel any outstanding warrants or options owned by him. See “Note 7” regarding a lawsuit filed by the Company against Mr.Chason.
	On December 11, 2012, Mr. Wiechnik resigned from the Board of Directors and agreed to cancel any outstanding options or warrants in exchange for the issuance of 500,000 shares of restricted Common Stock, subject to a 9-month lock-up through September 11, 2013. Mr. Wiechnik also agreed to cancel any outstanding consulting fees, director compensation and/or expenses owed to him as of the execution date of said agreement.

Stock_Option_Plan

Stock Option Plan	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
11. Stock Option Plan	'
	On August 8, 2013, the Board of Directors approved the 2013 Employee Benefit and Consulting Services Compensation Plan which has 15,000,000 shares that may be issued under said Plan. The Plan provides for the direct issuance of shares of common stock under the Plan and for the grant of non-statutory stock options on terms established by the Board of Directors or committee thereof. While the Plan does not require stockholder approval to be implemented, in the event stockholder approval is obtained on or before August 8, 2014, then incentive stock options could be granted under the Plan. In September 2013, the Company issued 6,000,000 shares of stock under said Plan to Douglas Beplate pursuant to his consulting contract described in Note 8.
	A summary of the activity under the 2013 Employee Benefit and Consulting Services Compensation Plan as of December 31, 2013, and changes during the year then ended is presented below:
	Options
	Outstanding at January 1, 2013	7,025,000
	Forfeited	(4,875,000	)
	Outstanding at December 31, 2013	2,150,000

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
12. Subsequent Events	'
	On January 18, 2014, the Company entered into a consulting agreement with Steve Z. Safran to assist the Company in the areas of corporate networking, sales, marketing and strategic planning. Pursuant to said agreement, the Company issued 200,000 shares of restricted stock and immediately upon executing the agreement an option to purchase an additional 300,000 shares of stock at $0.12 per share.
	The Company’s Management has evaluated subsequent events through April 15, 2014 and there are none except as described herein.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Consolidation	'
	The accompanying consolidated financial statements include the accounts of the Company and its former wholly owned subsidiary, Epic Wound Care, Inc. (which was recently dissolved by the State of Florida), as of the dates and for the fiscal years indicated. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.
Income Taxes	'
	The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities which is commonly known as the asset and liability method. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	The Company evaluates its tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are ‘‘more-likely-than-not’’ of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are recorded as an expense in the applicable year. The Company does not have a liability for any unrecognized tax benefits. Management’s evaluation of uncertain tax positions may be subject to review and adjustment at a later date based upon factors including, but not limited to, an on-going analysis of tax laws, regulations and interpretations thereof, with due consideration given to the fact that tax periods are open to examination by tax authorities. Management believes the Company is no longer subject to income examinations for years prior to 2010.
	As of December 31, 2013, the Company has approximately $6.1 million of net operating loss carry-forwards available to affect future taxable income and has established a valuation allowance equal to the tax benefit of the net operating loss carry forwards and temporary differences as realization of the asset is not assured.
Revenue Recognition	'
	The Company recognizes revenues when persuasive evidence of an arrangement exists, product has been delivered or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is recognized net of estimated sales returns and allowances.
	Revenues are attributable to the sale of medical products through distributor agreements. The principal terms of the agreements provide that the distributor orders be accompanied by partial payment in advance, which at least equals 50% of total manufactured cost, as defined, for orders for distributor inventory and, in addition, an agreed portion of the distributor’s gross profit on special orders. The balance of the manufactured cost is due from the distributor at the time of shipment. The Company is also entitled to an agreed percentage of the distributor’s profit on receipt by the distributor. The Company defers all amounts received in advance of shipment and recognizes as revenue the aggregate of amounts invoiced in advance and an estimate of the Company’s portion of distributor’s profit at the time of shipment.
Per Share Information	'
	Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted loss per share is the same as basic loss per share, as the effect of potentially dilutive securities (8,150,000 options and 1,698,378 warrants at December 31, 2012 and 2,650,000 options and 1,698,378 warrants at December 31, 2013), is anti-dilutive.
New Accounting Pronouncements	'
	Recently Adopted Accounting Pronouncements
	In July 2012, the FASB issued an Accounting Standards Update that added an optional qualitative assessment for determining whether an indefinite-lived intangible asset is impaired. The objective of this update is to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by allowing an entity the option to make a qualitative evaluation about the likelihood of an intangible impairment to determine whether it should calculate the fair value of the asset. This accounting standards update also amends existing guidance by expanding upon the examples of events and circumstances that an entity should consider between annual impairment tests in determining whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount.

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions Tables	'
Transactions with LeadDog Capital LP	'
		Year Ended December 31,
		2013		2012
	Balance at beginning of period	$	448,099	$	409,398
	New borrowings at 16% interest rate		-		1,987
	Interest accrued		56,504		56,039
	Amortization of loan discount		-		-
	Redemption of indebtedness by the issuance shares of common stock		-		(19,325	)
	Repayment		-		-
	Balance at end of period	$	504,603	$	448,099

Stock_Option_Plan_Tables

Stock Option Plan (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Option Plan Tables	'
Employee Benefit and Consulting Services Compensation Plan	'
	A summary of the activity under the 2013 Employee Benefit and Consulting Services Compensation Plan as of December 31, 2013, and changes during the year then ended is presented below:
	Options
	Outstanding at January 1, 2013	7,025,000
	Forfeited	(4,875,000	)
	Outstanding at December 31, 2013	2,150,000

Significant_Accounting_Policie2

Significant Accounting Policies (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Notes to Financial Statements	'	'
Net operating loss carry-forwards	$6,100,000	'
Options, anti-dilutive	2,650,000	8,150,000
Warrants, anti-dilutive	1,698,378	1,698,378

Acquisition_of_Intellectual_Pr1

Acquisition of Intellectual Property Rights (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Notes to Financial Statements	'	'
Amortization charge	$100,000	$100,000

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Notes to Financial Statements	'	'
Balance at beginning of period	$448,099	$409,398
New borrowings at 16% interest rate	'	1,987
Interest accrued	56,504	56,039
Amortization of loan discount	'	'
Redemption of indebtedness by the issuance shares of common stock	'	-19,325
Repayment	'	'
Balance at end of period	$504,603	$448,099

Related_Party_Transactions_Det1

Related Party Transactions (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Related Party Transactions Details Narrative	'	'
Unpaid interest	$152,952	$96,448

Other_Current_Liabilities_Deta

Other Current Liabilities (Details Narrative) (USD $)	Dec. 31, 2013
Outstanding notes	$136,100
Maximum [Member]	'
Interest accrues	14.00%
Minimum [Member]	'
Interest accrues	9.00%

Stock_Option_Plan_Details

Stock Option Plan (Details)	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Outstanding at January 1, 2013	7,025,000
Forfeited	-4,875,000
Outstanding at December 31, 2013	2,150,000